FDA Fast-Tracks Bladder Cancer Drug with Landmark Trial Results

NEW YORK, NY – April 20, 2026 – The U.S. Food and Drug Administration (FDA) has granted Priority Review to a promising new combination therapy for muscle-invasive bladder cancer (MIBC), signaling a potential paradigm shift in how this aggressive disease is treated. Astellas Pharma and Pfizer announced today that their supplemental Biologics License Application (sBLA) for PADCEV™ (enfortumab vedotin-ejfv) combined with Keytruda® (pembrolizumab) has been accepted for expedited review.

The application seeks to expand the use of this perioperative regimen—administered before and after surgery—to all patients with MIBC, regardless of their eligibility for traditional cisplatin-based chemotherapy. With a target decision date set for August 17, 2026, under the Prescription Drug User Fee Act (PDUFA), patients and clinicians may soon have access to what could become the first and only therapy of its kind for this broad patient population, potentially establishing a new standard of care.

A New Era for Bladder Cancer Treatment

Muscle-invasive bladder cancer is a formidable foe. Accounting for about 30% of all bladder cancer cases, it is characterized by tumors that have grown into the bladder's muscle wall, increasing the risk of spreading to other parts of the body. For decades, the standard approach has been neoadjuvant (pre-surgery) chemotherapy with cisplatin, followed by a radical cystectomy to remove the bladder.

However, this strategy has significant limitations. Nearly half of all patients are ineligible for cisplatin due to other health issues, such as kidney problems. Even among those who can tolerate the full treatment course, the prognosis remains uncertain. More than 50% of patients who undergo curative-intent surgery will experience a recurrence of their cancer, a stark statistic that highlights a profound unmet medical need.

The sBLA submission is built on the strength of the Phase 3 EV-304 clinical trial, whose results, presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium, were nothing short of remarkable. The study showed that the PADCEV and Keytruda combination dramatically outperformed standard chemotherapy. Patients receiving the combination therapy saw a 47% reduction in the risk of tumor recurrence, progression, or death. Furthermore, the regimen demonstrated a 35% reduced risk of death overall compared to the chemotherapy arm.

"The data from the EV-304 trial take us another step closer to bringing perioperative enfortumab vedotin plus pembrolizumab to patients with muscle-invasive bladder cancer regardless of cisplatin eligibility," said Moitreyee Chatterjee-Kishore, PhD, MBA, Head of Oncology Development at Astellas. She emphasized that patients "still face a recurrence rate of more than fifty percent despite curative-intent surgery, highlighting the ongoing need for improved treatment strategies."

One of the most striking findings was the pathological complete response (pCR) rate—the absence of any detectable cancer in tissue samples after surgery. An impressive 55.8% of patients in the combination therapy arm achieved pCR, compared to just 32.5% in the chemotherapy group.

The Power of a Strategic Combination

The success of the EV-304 trial lies in the synergistic action of its two components, a collaboration of pharmaceutical giants Astellas, Pfizer, and Merck (which developed Keytruda). PADCEV is an antibody-drug conjugate (ADC), a highly targeted therapy often described as a "smart bomb." It seeks out a protein called Nectin-4, which is highly expressed on the surface of bladder cancer cells. Once bound, it delivers a potent anti-tumor agent directly inside the cell, causing it to self-destruct.

Keytruda, a cornerstone of modern immunotherapy, is a PD-1 inhibitor. It works by blocking a pathway that cancer cells use to hide from the immune system, effectively taking the "brakes" off immune cells and allowing them to recognize and attack the cancer. By combining PADCEV's direct cell-killing ability with Keytruda's immune-boosting power, the therapy launches a two-pronged assault on the tumor.

This combination is already approved for patients with locally advanced or metastatic urothelial cancer. This new application, if successful, would move the potent therapy into an earlier, curative-intent setting for a much broader group of patients.

"For people with muscle‑invasive bladder cancer, surgery is often just the beginning of a long and uncertain journey, with far too many patients seeing their cancer return," commented Jeff Legos, PhD, MBA, Chief Oncology Officer at Pfizer. "If approved, perioperative PADCEV plus pembrolizumab could meaningfully change that experience, potentially helping patients reduce the risk of recurrence and live longer, regardless of whether they are eligible for cisplatin."

Navigating the Regulatory Fast Track

The FDA's decision to grant Priority Review underscores the agency's belief that this therapy, if approved, could represent a significant improvement in the treatment of a serious condition. This designation shortens the review timeline from the standard ten months to just six, reflecting the urgency of getting potentially life-altering treatments to patients faster.

This expedited pathway is part of a broader effort by the FDA's Oncology Center of Excellence to streamline the evaluation of promising cancer drugs. While Priority Review does not guarantee approval, it is a strong positive signal about the quality and importance of the clinical data submitted. Historically, oncology drugs receiving this designation have a high rate of approval.

The safety profile observed in the EV-304 trial was reported as consistent with prior experience with the combination, with no new safety signals emerging. However, like many powerful cancer treatments, the regimen carries risks. Known side effects include serious skin reactions, hyperglycemia, peripheral neuropathy, and ocular disorders, which require careful monitoring and management by healthcare professionals.

A Hopeful Outlook for Patients

For the estimated 85,000 people diagnosed with bladder cancer in the U.S. each year, this development offers a new wave of optimism. The potential approval would not only provide a more effective option but also democratize access to it by removing the barrier of cisplatin eligibility.

If the FDA gives the green light in August, the PADCEV and Keytruda combination would be the first therapy approved for the perioperative setting in MIBC for all patients, marking a pivotal moment in the fight against this disease. The companies have also stated their intent to discuss the data with other global health authorities, suggesting that this new standard of care could eventually benefit patients worldwide. This milestone represents a significant step forward, offering the prospect of longer, cancer-free lives for thousands of patients who previously faced a much more uncertain future.